Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451169 | 1.00 | EPHX1 (0.61) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL272604 | 1.00 | EPHX1 (0.61) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL28839661 | 0.98 | EPHX1 (0.58) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL8422879 | 0.89 | SLC6A2 (0.57) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL28893947 | 0.89 | SLC6A2 (0.56) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL17463566 | 0.87 | EPHX1 (0.52) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL9323047 | 0.87 | EPHX1 (0.52) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL17887234 | 0.87 | ACP3 (0.51) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL9322166 | 0.87 | MAOB (0.50) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL3289611 | 0.85 | SLC6A4 (0.52) | EPHX1SLC6A2TAAR1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4224457-A | Process for manufacturing optically active sulfur-containing carboxylic acid | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1980-09-23 | — | — | US | claimed |
| CN-114375290-B | Novel synthetic options for preparing compounds | 百时美施贵宝公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-114375290-A | Novel synthetic options for the preparation of (6R,10S) -10- {4- [ 5-chloro-2- (4-chloro-1H-1, 2, 3-triazol-1-yl) phenyl ] -6-oxo-1 (6H) -pyrimidinyl } -1- (dioxomethyl) -6-methyl-1, 4,7,8,9, 10-hexahydro-11, 15- (methylenebridging) pyrazolo [4,3-B ] [1,7] diazacyclotetradecyn-5 (6H) -one | 百时美施贵宝公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220048856-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3901137-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020125536-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | 浙江华海药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2017091453-A1 | NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| EP-0470127-A1 | PCP RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1992-02-12 | — | — | EP | disclosed |
| CN-1014885-B | Asymmetric synthesis of optically active alpha-substituted benzylamines | CHENGDU ORGANIC CHEM INST (CN) | 1991-11-27 | — | — | CN | disclosed |
| US-5011834-A | Treating or preventing neuronal loss in ischemia, hypoxia, brain and spinal cord trauma, Alzheimer*s | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1991-04-30 | — | — | US | disclosed |
| WO-1990012575-A1 | PCP RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1990-11-01 | — | — | WO | disclosed |
| CN-1039582-A | The method of asymmetric synthesis of optical activity α-Qu Daibianan | CHENGDU ORGANIC CHEM INST (CN) | 1990-02-14 | — | — | CN | disclosed |
| EP-0246195-B1 | OPTICALLY ACTIVE IRIDIUM COMPLEXES AND THEIR USE | CIBA-GEIGY AG (CH) | 1989-12-13 | — | — | EP | disclosed |
| EP-0246196-B1 | OPTICALLY ACTIVE IRIDIUM COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1989-10-25 | — | — | EP | disclosed |
| US-4855432-A | HYDROGENATION CATALYST IN TRANSFER HYDROGENATION OF PROCHIRAL KETONES | CIBA-GEIGY CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4851534-A | ENANTIOSELECTIVE HYDROGENATION CATALYST | CIBA-GEIGY CORPORATION (US) | 1989-07-25 | — | — | US | disclosed |
| US-4224457-A | Process for manufacturing optically active sulfur-containing carboxylic acid | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | EPHX1 2634/4885SLC6A2 2118/4885TAAR1 3814/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | EPHX1 3510/4885SLC6A2 1030/4885TAAR1 3871/4885 |
| US-20220048856-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | BLVRB, QDPR, CYP4B1 | EPHX1 1578/4885SLC6A2 2656/4885TAAR1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.